论文部分内容阅读
对乙型慢性肝炎的一种新型免疫赋活剂cianida-nol已引起注意。它属于黄酮类药物,在欧洲,临床应用于酒精性肝脏病。现在,经日本厚生省批准的乙型慢性肝炎药物有干扰素β和cianidanol两种,cian-idanol几乎没有干扰素那样发热等副作用,可口服,患者不需住院。cianidanol对HBeAg阳性的慢性肝炎治疗试验,是厚生省特定疾病“难治性肝炎”调查研究班的重点,在全日本74个医疗单位进行了统一的双盲法试验,证实cianidanol组比安慰剂组有明显的改善。前者HBeAb阳性化6.4%,HBeAg阴性化16.1%,
Cianida-nol, a novel immune activator of type B chronic hepatitis, has drawn attention. It belongs to flavonoids, in Europe, clinical application of alcoholic liver disease. At present, hepatitis B chronic hepatitis drugs approved by the Japanese Ministry of Health and Welfare contain interferon β and cianidanol. Cian-idanol has almost no side effects such as fever due to interferon. It can be taken orally and patients do not need to be hospitalized. cianidanol HBeAg-positive chronic hepatitis treatment trials, is the Ministry of Health and disease-specific disease “refractory hepatitis” research class focused on 74 medical units in Japan conducted a unified double-blind trial confirmed cianidanol group than in the placebo group was significantly Improvement. The former HBeAb positive 6.4%, HBeAg negative 16.1%